SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories’ Q2 net profit jumps up by 60%

25 Oct 2012 Evaluate

Ipca Laboratories has reported results for second quarter ended September 30, 2012.

The company has reported a surge of 60.45% in its net profit at Rs 125.09 crore for the quarter ended September 30, 2012 as compared to Rs 77.96 crore for the same quarter in the previous year. The company’s total income has increased by 24.56% at Rs 780.45 crore for quarter under review as compared to Rs 626.55 crore for the quarter ended September 30, 2011.

Pursuant to the scheme of amalgamation of Tonira Pharma with the Company with effect from appointed date April 01, 2011, the results of operations for the quarter and half year ended September, 2012 includes the operations of the business of erstwhile Tonira. Since this effect of amalgamation was given in the quarter ended March, 2012, the figure of the comparative quarter and half year ended September, 2011 does not include the result of operations of the erstwhile Tonira and hence not comparable.

Further, the company’s board of directors at its meeting held on October 25, 2012, has declared an interim dividend of 100% (Rs 2 per share) for the financial year 2012-13.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Ipca Laboratories Share Price

1537.30 -6.65 (-0.43%)
06-May-2026 09:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1839.85
Dr. Reddys Lab 1292.95
Cipla 1339.00
Zydus Lifesciences 919.85
Lupin 2360.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×